This case describes a patient with pancreatic NET associated with EAS, in whom treatment with the somatostatin analog octreotide became much more effective in controlling cortisol and ACTH after the addition of GR antagonist therapy with mifepristone. This evidence concerns the gene NR3C1 and pancreatic neuroendocrine tumor.